Molecular markers play an increasingly important role in managing urologic cancers. In this test-specific episode of the "Answers From the Lab" podcast, Sounak Gupta, M.B.B.S., Ph.D., explains why Mayo Clinic Laboratories' urologic NGS panels are a cost-effective way to inform prognosis and individualized treatment.

"The new test panels fill a void between single gene assays and our large solid tumor panel," Dr. Gupta says. "Within a small, targeted panel, we can address a lot of questions collectively."

Mayo Clinic urologists, oncologists, and geneticists helped determine which genes to include. "We've tried to cover the most relevant diagnostic, therapeutic and prognostic biomarkers in a disease-specific manner for kidney, bladder, and prostate cancer," Dr. Gupta says.

Some of the panels (noted below) also evaluate microsatellite instability status to help guide immunotherapy selection. "These very carefully curated panels are tools for multiple groups that help us better serve our patients," Dr. Gupta says.

Listen to learn more about Mayo Clinic Laboratories' MayoComplete urologic panels.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

MCKCP | MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 30 genes.
• Evaluates for microsatellite instability status.

MCBPP | MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 39 genes.
• Evaluates for microsatellite instability status.

MCFRC | MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic insights based on assessment of four genes.

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less